**Core Concept**
Achalasia is a motility disorder of the esophagus characterized by difficulty in swallowing due to impaired relaxation of the lower esophageal sphincter (LES) and abnormal peristalsis. The pathophysiology involves an imbalance between excitatory and inhibitory neurotransmitters, leading to sustained contraction of the LES and impaired esophageal clearance.

**Why the Correct Answer is Right**
Beta blockers are not a standard treatment for achalasia. The primary pharmacologic therapies for achalasia include nitrates, which relax the LES by releasing nitric oxide, and calcium channel blockers, which inhibit calcium entry into smooth muscle cells of the LES, leading to relaxation. Botulinum toxin injections into the LES can also provide temporary relief by blocking acetylcholine release. Sildenafil, a phosphodiesterase-5 inhibitor, can also help relax the LES by increasing nitric oxide levels.

**Why Each Wrong Option is Incorrect**
**Option A:** Nitrates are a correct therapeutic option for achalasia, as they relax the LES and improve esophageal clearance.
**Option C:** Botulinum toxin injections are a recognized treatment for achalasia, providing temporary relief by blocking acetylcholine release.
**Option D:** Sildenafil is also a valid treatment for achalasia, helping to relax the LES by increasing nitric oxide levels.

**Clinical Pearl / High-Yield Fact**
Achalasia is a classic example of a motility disorder, and its pathophysiology involves an imbalance between excitatory and inhibitory neurotransmitters. The key to management is identifying and addressing this imbalance through pharmacologic or procedural interventions.

**Correct Answer:** **✓ Correct Answer: B. Beta blockers.**